Retrospective serological and molecular survey of myxoma or antigenically related virus in the Iberian hare, Lepus granatensis.
ELISA
Iberian Peninsula
Iberian hare
Lepus granatensis
emerging disease
ha-MYXV
hare diseases
lagomorph diseases
myxoma virus
myxomatosis
qPCR
recombination
Journal
Transboundary and emerging diseases
ISSN: 1865-1682
Titre abrégé: Transbound Emerg Dis
Pays: Germany
ID NLM: 101319538
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
revised:
10
08
2022
received:
17
12
2021
accepted:
05
10
2022
pubmed:
12
10
2022
medline:
7
2
2023
entrez:
11
10
2022
Statut:
ppublish
Résumé
The 2018 outbreak of myxomatosis in the Iberian hare (Lepus granatensis) has been hypothesized to originate from a species jump of the rabbit-associated myxoma virus (MYXV), after natural recombination with an unknown poxvirus. Iberian hares were long considered resistant to myxomatosis as no prior outbreaks were reported. To provide insights into the emergence of this recombinant virus (ha-MYXV), we investigated serum samples from 451 Iberian hares collected over two time periods almost two decades apart, 1994-1999 and 2017-2019 for the presence of antibodies and MYXV-DNA. First, we screened all serum samples using a rabbit commercial indirect ELISA (iELISA) and then tested a subset of these samples in parallel using indirect immunofluorescence test (IFT), competitive ELISA (cELISA) and qPCR targeting M000.5L/R gene conserved in MYXV and ha-MYXV. The cut-off of iELISA relative index 10 = 6.1 was selected from a semiparametric finite mixture analysis aiming to minimize the probability of false positive results. Overall, MYXV related-antibodies were detected in 57 hares (12.6%) including 38 apparently healthy hares (n = 10, sampled in 1994-1999, none MYXV-DNA positive, and n = 28 sampled in 2017-2019 of which four were also ha-MYXV-DNA positive) and 19 found-dead and ha-MYXV-DNA-positive sampled in 2018-2019. Interestingly, four seronegative hares sampled in 1997 were MYXV-DNA positive by qPCR, the result being confirmed by sequencing of three of them. For the Iberian hares hunted or live trapped (both apparently health), seroprevalence was significantly higher in 2017-2019 (13.0%, CI95% 9.2-18.2%) than in 1994-1999 (5.4%, CI95% 3.0-9.6%) (p = .009). Within the second period, seroprevalence was significantly higher in 2019 compared to 2017 (24.7 vs 1.7% considering all the sample, p = .007), and lower during the winter than the autumn (p < .001). While our molecular and serological results show that Iberian hares have been in contact with MYXV or an antigenically similar virus at least since 1996, they also show an increase in seroprevalence in 2018-2019. The remote contact with MYXV may have occurred with strains that circulated in rabbits, or with unnoticed strains already circulating in Iberian hare populations. This work strongly suggests the infection of Iberian hares with MYXV or an antigenically related virus, at least 20 years before the severe virus outbreaks were registered in 2018.
Identifiants
pubmed: 36219552
doi: 10.1111/tbed.14734
pmc: PMC10092749
doi:
Substances chimiques
DNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3637-3650Subventions
Organisme : Fundo Florestal Permanente, Government of Portugal
ID : 2019014300001
Organisme : The Action Plan for the Control of Rabbit Viral Haemorrhagic Disease
Organisme : The Spanish Ministry of Science and Innovation
ID : PID2019-111080RB-C21
Organisme : Fundação para a Ciência e Tecnologia (FCT)
ID : SFRH/BD/137067/2018
Organisme : Fundação para a Ciência e Tecnologia (FCT)
ID : UIDB/CVT/00772/2020
Organisme : Fundação para a Ciência e Tecnologia (FCT)
ID : AL4LA/P/0059/2020
Organisme : Fábio A. Abade dos Santos
ID : SFRH/BD/137067/2018
Organisme : The European Regional Development Fund
ID : SBPLY/17/180501/000514
Informations de copyright
© 2022 The Authors. Transboundary and Emerging Diseases published by Wiley-VCH GmbH.
Références
Res Vet Sci. 2017 Oct;114:281-286
pubmed: 28558359
mBio. 2022 Apr 26;13(2):e0346121
pubmed: 35352978
Viruses. 2015 Mar 06;7(3):1020-61
pubmed: 25757062
Transbound Emerg Dis. 2019 Nov;66(6):2204-2208
pubmed: 31293076
Stat Med. 2006 Sep 15;25(17):2994-3010
pubmed: 16345022
Sci Rep. 2022 Jun 3;12(1):9310
pubmed: 35661130
Vet Parasitol. 2016 Dec 15;232:36-42
pubmed: 27890080
J Virol Methods. 2014 Feb;196:219-24
pubmed: 24300832
Res Vet Sci. 2022 May;144:149-156
pubmed: 34815105
Prev Vet Med. 2016 Feb 1;124:45-51
pubmed: 26791753
Transbound Emerg Dis. 2022 Nov;69(6):3637-3650
pubmed: 36219552
Am J Epidemiol. 2017 Jan 15;185(2):124-134
pubmed: 28062393
Viruses. 2021 Jun 16;13(6):
pubmed: 34208752
Prev Vet Med. 2010 Jan 1;93(1):42-50
pubmed: 19818517
Transbound Emerg Dis. 2022 Jul;69(4):1684-1690
pubmed: 35366052
Rev Sci Tech. 2015 Aug;34(2):549-56, 539-47
pubmed: 26601455
Antiviral Res. 2012 Mar;93(3):387-415
pubmed: 22333483
Science. 2019 Mar 22;363(6433):1319-1326
pubmed: 30765607
Transbound Emerg Dis. 2021 May;68(3):1275-1282
pubmed: 32786107
Ann Inst Pasteur (Paris). 1954 Jan;86(1):105-7
pubmed: 13158933
Rev Sci Tech. 1998 Apr;17(1):256-68
pubmed: 9638815
Animals (Basel). 2019 Oct 10;9(10):
pubmed: 31658748
Integr Zool. 2017 Jan;12(1):49-60
pubmed: 27264936
Proc Biol Sci. 2014 Jul 7;281(1786):
pubmed: 24827436
BMC Res Notes. 2011 Nov 16;4:498
pubmed: 22087883
PLoS One. 2020 Apr 17;15(4):e0231795
pubmed: 32302375
Viruses. 2020 Oct 05;12(10):
pubmed: 33028004
Int J Mol Sci. 2021 Nov 07;22(21):
pubmed: 34769480
Vet Rec. 2014 Jul 19;175(3):75-6
pubmed: 25034685
J Hyg (Lond). 1975 Oct;75(2):237-47
pubmed: 1058245
Vaccine. 2010 Jul 26;28(33):5414-20
pubmed: 20598407
Pathogens. 2019 Jul 27;8(3):
pubmed: 31357631
Prev Vet Med. 2007 Oct 16;81(4):290-305
pubmed: 17574284
Viruses. 2019 Jun 07;11(6):
pubmed: 31181645
J Wildl Dis. 1995 Oct;31(4):541-4
pubmed: 8592388
PLoS Negl Trop Dis. 2017 Jan 18;11(1):e0005230
pubmed: 28099433
Transbound Emerg Dis. 2019 Nov;66(6):2218-2226
pubmed: 31322320
Vaccines (Basel). 2022 Feb 24;10(3):
pubmed: 35334987
Transbound Emerg Dis. 2021 Jul;68(4):2616-2621
pubmed: 33119958